Theodor Bilharz Research Institute The Eighth Annual Scientific Meeting In Hepatogastroenterology between Theodor Bilharz Research Institute and Beaujon Hospital (France) Tuesday the 5 th of April 2016 10 AM (one day meeting) Main Hall of the Institute President of Theodor Bilharz Research institute Prof. Dr. Youssef Farouk Coordinators Theodor Bilharz- Beaujon Hospital Agreement Prof. Dr. Ahmed El Ray Prof. Dr. Philippe Ruszniewski
Scientific Program Opening Ceremony &Welcome Speech 10:00 AM Professor Ahmed EL RAY Moderator of the meeting, Egyptian Coordinator of TBRI - Beaujon Agreement Professor Francois DURAND The head of the hepatology and Liver Intensive Care Unit in Beaujon Hospital. Mr Louis MOREAU The scientific attaché of the French Embassy in Egypt Professor Youssef FAROUK President of Theodor Bilharz Research Institute Session I 11:00 AM - 12:30 PM Chairpersons: Prof Ali Gaballah, Prof Ahmed Abd El-Aziz, Prof Mostafa El-Shazly, Prof Magdy Elserafy, Prof Alaa El Din Ismaeil Ewiss, Prof Emad Essmat Professor Valerie PARADIS Professor of Hepatic pathology at faculty of Medicine Paris Diderot university - Beaujon hospital Mixed hepatobiliary tumors: an emerging entity Dr Safi DOKMAK Consultant Surgeon in the Hepatobiliary and Pancreatic Surgical department in Beaujon hospital Update in abdominal surgery in cirrhotic patients Professor Moataz SEYAM Professor of Hepatogastroenterology in Theodor Bilharz Research Institute Management of infection in liver transplantation setting
Coffee Break 12:30 PM - 01:00 PM Session II 1:00-2:00 PM Chairpersons: Prof Gamal Essmat, Prof Imam Waked, Prof Ayman Youssry, Prof Moataz Hassan, Prof Mahmoud Osman, Prof Mayssa El Raziky Professor Francois DURAND The head of the hepatology and Liver Intensive Care Unit in Beaujon Hospital, Clichy, and Professor of Hepatology at University Paris Diderot, Paris, France. Impact of new direct antiviral agents on the management of HCV-infected patients pre and post transplantation Professor Wahid Doss Professor of Tropical Medicine and Hepatology in Faculty of Medicine, Cairo university and the president of the national committee of viral Hepatitis The Egyptian National HCV control Program : Treatment outcome in the era of DAAs Session III 2:00 PM - 2:30 PM An interactive session, Meet the expert : Prof Francois Durand, Prof Valerie Paradis, Dr Safi Dokmak, Prof Wahid Doss, Prof Moataz siam Moderators of the session : Prof Hesham ElKhayat - Prof Ahmed El Ray
Coardinators of Theodor Bilharz - Beaujon Hospital Agreement Professor Philippe Ruszniewski Professor Patrick Marcellin Professor Ahmed El Ray Professor Nevine Fam Congratulations to Professor Philippe Ruszniewski! Professor Philippe Ruszniewski, the man of science and ethics, is now the dean of the faculty of Medicine Paris Diderot University. Professor Ruszniewski is the godfather of the Beaujon Bilharz agreement. He promised us keeping the support of this fruitful cooperation. Orgnizing commitee Professor Nevine Fam Dr. Ahmed Youssef Montasser Mrs. Tahra Abd El Moneim Mr. Mahmoud Abd Rabo Thanks to sponsors of the meeting The meeting was made possible through the generous unrestricted support from the pharmaceutical companies.
Thanks to Professor Alaa Ismail, the head of the Clinical Medical department Thanks to all my professors and colleagues members of the Hepatogastroenterology department: Prof Nawal El-Badrawy - Prof Moataz Hassan - Prof Ahmed Sadek - Prof Gamal El-Attar Prof Magdy Youssef - Prof Ibrahim Mostafa Prof Naglaa El-Sherif Prof Hesham El-Khayat - Prof Maged El-Ghannam Prof Youssry Abdel-Rahman - Prof Sameh Fakhry - Prof Alaa Awad -Prof Shendy Mohamed - Prof Moataz Seyam - Prof Mahmoud El Ansary Assistant Professors: Dr. Wael Safwat Dr. Raafat Atta Dr Abdel-Aziz Ali - Dr Mohamed Darwish Dr Ayman Abdel Aziz. Dr Sherif Morsy Dr Mohamed Aboelez- Dr Ahmed Gamal Dr Ahmed Abdel-azeem Dr Ahmed Rashad Dr Aly Abdelrehim Dr Mohamed Elkady Dr Mostafa Ibrahim Dr Walid Soliman Dr Khaled Ragab Dr Mohamed Abdel-Badih Dr Mahmoud ElSherbini Dr Mohamed El-Refaaei Dr Mohamed Ragab - Dr. Amr Abd ELAzim Dr. Hany Ezzat, Dr. Mohamed Lashin, Dr. Sara Mamdouh, Dr. Mohamed Abd El-moneim, Dr. Mohamed Attia, Dr. Mohamed Dwidar, Dr. Mariam Ahmed Fayed
Professor Francois DURAND French Speakers Dr François Durand is the head of the hepatology and Liver Intensive Care Unit in Hospital Beaujon, Clichy, and Professor of Hepatology at University Paris Diderot, Paris, France. His main topics are the management of advanced cirrhosis, acute-on-chronic liver failure, acute liver failure and transplantation. He has been involved in a number of research programs in the field. Professor Valerie PARADIS Professeur des Universités- Praticien Hospitalier in Pathology (Commission Nationale des Universités) Université Paris 7) Dr Paradis joined the Pathological department of Beaujon hospital in 2002 to mainly take over pathological activity from Liver surgery and liver transplantation (Pr J Belghiti, Pr D Valla &F Durand). From 2008 to date, she have been the co-leader with Pr P Bedossa of the research team From cirrhosis to cancer: Physiopathology and diagnosis (Inserm U773 CRB3). For the next 5-year INSERM contract (2014-), she leads one of the teams belonging to the Research Center on Inflammation (INSERM U1149, Director Pr R Monteiro). She is an Elected member :CNU (national council of University) 2010-, Scientific commissions Research Institutes INSERM CSS6 (2008-2012), ANRS CSS4 (2011-), Association Française de l Etude du Foie (AFEF 2012-), administrative board, European Society of Pathology Digestive Diseases Working Group (Secretary, 2011-). She received a Personal Awards : Lauréate de la prime d excellence scientifique (2009). Dr Safi DOKMAK Dr Safi Dokmak is one of the surgeons in Hepatobiliary and Pancreatic surgical department in Beaujon hospital. He worked with Professeur Jacques Belghiti for more then 10 years, the main surgical activity is in open and laparoscopic liver and pancreas surgery and he is one of the leading surgeon in the development of laparoscopic pancreatic surgery, also he shows high activity in liver and small bowel transplantation, he contribute to many innovations in this field.
Egyptian Speakers Professor Wahid DOSS Dr Wahid Doss is Professor of Hepatogastroenterolgy and Endemic Medicine at Cairo University. He became the Head of the National Hepatology Institute, Cairo from 2006 till 2015. He is the Head of the National Committee for the control of viral Hepatitis from 2006 till present. Together with his colleagues, he established and supervised one of the most comprehensive Hepatitis treatment programs worldwide, which has received acclaim from local and international organizations including the WHO. He is a founding member of the GI endoscopy unit at Kasr ElAini hospital, Cairo University and has special interest in therapeutic endoscopic procedures. He is a member of EASL, AASLD and ASGE. He is a founding member and current vice-president of the Egyptian Liver Care Society. Professor Moataz SEYAM Dr Moataz seyam professor of hepatoloy and gastroenterology. Member of American Association For the Study of liver disease AASLD (2004). He is interested in the management of viral hepatitis. and liver transplantation. He is a member of a leading team that started living liver transplantion in Egypt (2001). He spent two years as research fellow at liver transplantation unit, Queen Elizabeth Hospital, Birmingham University, UK. He shared in the managment of three hundred living transplantation over the last eight years in Egypt.
Theodor Bilharz Research Institute El Nile St. Warak Elhadar P.Box 30, Imbaba Giza, 12411 Egypt Tel: 02-35041019/ 02-35408277 Fax: 02-35408125 President of TBRI Prof. Dr. Youssef Farouk In coopreation with Major Sponsors: Sponsors of the meeting: Sponsors: We apologize to the companies that participated after printing the program No commercial entity was involved in decisions regarding the development of the program and selection of the speakers. There has not been any condition of recommendation of any products associated with the support of the meeting. The core meeting is free from any commercial involvement. All The financial share of the sponsoring pharmaceutical companies is documented and declared.